67 results
DEFA14A
ORTX
Orchard Therapeutics plc
30 Nov 23
Additional proxy soliciting materials
4:13pm
with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
DEFA14A
ORTX
Orchard Therapeutics plc
21 Nov 23
Additional proxy soliciting materials
7:53am
materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
or business), which may be offset by U.S. source capital losses.
Information Reporting and Backup Withholding
Holders may, under certain circumstances … to individual UK Shareholders to offset against chargeable gains realized on the disposal of their Orchard ordinary shares.
Corporates
Subject
PREM14A
ORTX
Orchard Therapeutics plc
3 Nov 23
Preliminary proxy related to merger
5:11pm
or business), which may be offset by U.S. source capital losses.
Information Reporting and Backup Withholding
Holders may, under certain circumstances … to individual UK Shareholders to offset against chargeable gains realized on the disposal of their Orchard ordinary shares.
Corporates
Subject to any
DEFA14C
jxh2 4m55
5 Oct 23
Additional information
5:26pm
DEFA14C
95xxt4qc3 cw4
5 Oct 23
Additional information
4:48pm
DEFA14C
uz9vk5s wgflfg1w2
5 Oct 23
Additional information
4:45pm
DEFA14C
cmo dt4kbrml5
5 Oct 23
Additional information
4:43pm
DEFA14C
qcdrbbitsl h3e5rvfkl
5 Oct 23
Additional information
4:40pm
424B3
93q1aypgykv o3dta38n
21 Aug 23
Prospectus supplement
4:32pm
8-K
EX-99.2
xgg709i7 x03
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.1
gepon
15 May 23
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023
7:05am
8-K
EX-99.1
5z4r9
14 Nov 22
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
7:10am
8-K
EX-99.1
8hrnhgk
4 Aug 22
Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
7:05am